Prelude Therapeutics Incorporated filed its quarterly report on Form 10-Q with the SEC on November 16, 2026, covering the three and nine months ended September 30, 2026.

Key Highlights

  • Net loss of $12.544 million for the three months ended September 30, 2026, compared to a net loss of $19.725 million in the same period of 2025, according to the filing.
  • Revenue of $5.647 million for Q3 2026, down from $6.500 million in Q3 2025, as reported in the statements of operations.
  • Total assets of $175.485 million as of September 30, 2026, up from $141.315 million at December 31, 2025.
  • Total stockholders' equity of $124.136 million at September 30, 2026, compared to $68.637 million at December 31, 2025.
  • Accumulated deficit of $719.911 million as of September 30, 2026, versus $683.061 million at December 31, 2025.
  • 80,070,666 shares of voting and non-voting common stock outstanding as of November 11, 2026, per the filing cover page.
  • Common stock offering raised net proceeds with issuance costs of $4.557 million disclosed for the Q2 2026 share and prefunded warrant issuance, adding $85.443 million to stockholders' equity at that time.

Prelude Therapeutics Reports Reduced Operating Losses and Higher Asset Base for September 2026 Quarter

According to the filing, Prelude Therapeutics Incorporated (NASDAQ:PRLD) reported a net loss of $12.544 million for the three months ended September 30, 2026, a reduction from the $19.725 million net loss recorded in the same quarter of 2025. For the nine months ended September 30, 2026, the company reported a net loss of $36.850 million, compared to $83.041 million for the nine months ended September 30, 2025. Net loss per share, basic and diluted, was $(0.12) for Q3 2026 versus $(0.26) for Q3 2025, based on weighted average common shares outstanding of 103,091,149 and 76,132,337, respectively.

The company disclosed total operating expenses of $19.912 million for Q3 2026, consisting of $14.830 million in research and development costs and $5.082 million in general and administrative expenses. This compares to total operating expenses of $26.918 million in Q3 2025. Revenue was $5.647 million for the quarter ended September 30, 2026. Other income, net, was $1.721 million for Q3 2026, up from $693 thousand in Q3 2025. For the nine-month period, the company reported $7.046 million in other income, net, compared to $4.177 million in the prior-year period.

The balance sheet as of September 30, 2026 showed cash and cash equivalents of $23.412 million and marketable securities of $116.589 million, for total current assets of $142.427 million. Total liabilities declined to $51.349 million from $72.678 million at December 31, 2025, primarily reflecting a reduction in deferred revenue, which decreased from $35.532 million combined (current and non-current) at year-end 2025 to $19.601 million at September 30, 2026. Stockholders' equity grew to $124.136 million from $68.637 million at December 31, 2025, reflecting the Q2 2026 equity offering and ongoing stock-based compensation, partially offset by continued net losses.

What Was Disclosed

Prelude Therapeutics filed its unaudited quarterly financial statements for the period ended September 30, 2026, disclosing a reduced net loss year-over-year, a larger asset base driven by marketable securities, and increased stockholders' equity following an equity issuance completed during Q2 2026.